The latest announcement is out from Rapid Micro Biosystems ( (RPID) ).
On February 21, 2025, Rapid Micro Biosystems entered into a five-year global distribution and collaboration agreement with MilliporeSigma, a subsidiary of Merck KGaA. This agreement grants MilliporeSigma co-exclusive rights to sell Rapid Micro’s Growth Direct systems and related consumables globally, targeting industries such as pharmaceuticals, medical devices, and food and beverages. The partnership aims to expand Rapid Micro’s commercial reach and includes commitments from MilliporeSigma to purchase a minimum number of systems in the first two years. Additionally, the agreement outlines future collaborations on supply chain efficiencies and joint product development, potentially enhancing Rapid Micro’s market position and operational margins.
More about Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company that provides automation solutions to enhance the manufacturing and release of healthcare products, including biologics, vaccines, cell and gene therapies, and sterile injectables. The company’s flagship product, the Growth Direct system, modernizes microbial quality control testing in pharmaceutical manufacturing, offering faster results and improved data integrity. Headquartered in Lexington, Massachusetts, the company also has locations in Switzerland, Germany, and the Netherlands.
YTD Price Performance: 176.53%
Average Trading Volume: 290,575
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $116.6M
For an in-depth examination of RPID stock, go to TipRanks’ Stock Analysis page.